TABLE OF CONTENTS
Volume 60, Issue 3 (September 1996)
Pharmacokinetics and Drug Disposition |
Clinical Trials and Therapeutics |
Pharmacoepidemiology and Drug Utilization |
Grand Rounds |
Letters to the Editor |
Notes of the American Society for Clinical Pharmacology and Therapeutics |
American Society for Clinical Pharmacology and Therapeutics |
USAN Council
Commentaries
The complex interaction between ethanol and acetaminophen
John T. Slattery PhD, Sidney D. Nelson PhD and Kenneth E. Thummel PhD
Clin Pharmacol Ther 60: 241-246; doi:10.1016/S0009-9236(96)90050-8
The kinetics and dynamics of responses to placebo
Murray Weiner MD and George J. Weiner MD
Clin Pharmacol Ther 60: 247-254; doi:10.1016/S0009-9236(96)90051-X
Pharmacokinetics and Drug Disposition
Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine
Sylvie Laganière PhD, Richard F. Davies MD, PhD, Germain Carignan MSc, Kathy Foris MD, Lynne Goernert, Karen Carrier, Conrad Pereira PhD and Iain McGilveray PhD
Clin Pharmacol Ther 60: 255-264; doi:10.1016/S0009-9236(96)90052-1
Human pharmacokinetics of dihydroergotamine administered by nasal spray
Henri Humbert PhD, Marie-Danièle Cabiac, Claude Dubray MD and Danièle Lavène PhD
Clin Pharmacol Ther 60: 265-275; doi:10.1016/S0009-9236(96)90053-3
Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease
Sanjay Asthana MD, Nigel H. Greig PhD, Harold W. Holloway BS, Kathleen C. Raffaele PhD, Annamaria Berardi PhD, Mark B. Schapiro MD, Stanley I. Rapoport MD and Timothy T. Soncrant MD
Clin Pharmacol Ther 60: 276-282; doi:10.1016/S0009-9236(96)90054-5
The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment
Nimish N. Vachharajani PhD, Wen Chyi Shyu PhD, William R. Garnett PharmD, Elizabeth A. Morgenthien PhD and Rashmi H. Barbhaiya PhD
Clin Pharmacol Ther 60: 283-294; doi:10.1016/S0009-9236(96)90055-7
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
Deborah A. Capon BSc (Hons), Felix Bochner MD, FRACP, Nicole Kerry BSc (Hons), Gerd Mikus MD, Catherine Danz RN and Andrew A. Somogyi PhD
Clin Pharmacol Ther 60: 295-307; doi:10.1016/S0009-9236(96)90056-9
Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine
Jyrki Vanakoski MD, Timo Seppälä MD, PhD, Eeva Sievi PhD and Erik Lunell MD, PhD
Clin Pharmacol Ther 60: 308-315; doi:10.1016/S0009-9236(96)90057-0
Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers
Jörn Lötsch MD, Anne Stockmann, Gerd Kobal MD, Kay Brune MD, Rainer Waibel PhD, Norbert Schmidt PhD and Gerd Geisslinger PhD, MD
Clin Pharmacol Ther 60: 316-325; doi:10.1016/S0009-9236(96)90058-2
The effect of ingestion time interval on the interaction between itraconazole and triazolam
Pertti J. Neuvonen MD, PhD, Anu Varhe MD and Klaus T. Olkkola MD, PhD
Clin Pharmacol Ther 60: 326-331; doi:10.1016/S0009-9236(96)90059-4
Clinical Trials and Therapeutics
Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies
Ma del Mar Fernández de Gatta PharmD, Ma Victoria Calvo PharmD, Jesus M. Hernández MD, Dolores Caballero MD, Jesus F. San Miguel MD and Alfonso Domínguez-Gil PharmD
Clin Pharmacol Ther 60: 332-340; doi:10.1016/S0009-9236(97)90148-X
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine
Luigi Corea MD, Ondina Cardoni MD, Roberto Fogari MD, Pierfranco Innocenti MD, Carlo Porcellati MD, Michele Provvidenza MD, Susanne Meilenbrock BPharm, John Sullivan BSc and Frédéric Bodin MD
Clin Pharmacol Ther 60: 341-346; doi:10.1016/S0009-9236(96)90061-2
Pharmacoepidemiology and Drug Utilization
Adverse nondrug reactions: An update
Frank P. Meyer MD, Uwe Tröger and Friedrich-Wilhelm Röhl PhD
Clin Pharmacol Ther 60: 347-352; doi:10.1016/S0009-9236(96)90062-4
Grand Rounds
Medical histories may be unreliable in screening volunteers for clinical trials
Glen Apseloff MD, Judy K. Swayne and Nicholas Gerber MB,BS
Clin Pharmacol Ther 60: 353-356; doi:10.1016/S0009-9236(96)90063-6
Letters to the Editor
Publishing Summary Basis of Approval
Stots B. Reele
Clin Pharmacol Ther 60: 357; doi:10.1016/S0009-9236(96)90064-8
Note from the editor
Marcus M. Reidenberg MD Editor
Clin Pharmacol Ther 60: 357; doi:10.1016/S0009-9236(96)90065-X
Notes of the American Society for Clinical Pharmacology and Therapeutics
Nominations for Awards
Clin Pharmacol Ther 60: 358-359; doi:10.1016/S0009-9236(96)90066-1
American Society for Clinical Pharmacology and Therapeutics
A message from the Ethics Committee chairman
Alan W. Dunton MD
Clin Pharmacol Ther 60: 360; doi:10.1016/S0009-9236(96)90067-3
